About
Pricing
FAQs
Providers
Trials
Blog
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
No phase
Who can join
Healthy volunteers too
Searching
1–20 of 340
Completed
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of two doses of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with…
NCT00253188
Recruiting
Epidemiology and Biomarker Study in Alzheimer's Disease
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
NCT07142954
·
Houston, Texas and 3 others
Completed
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.
NCT04947553
·
Peoria, Arizona and 46 others
Terminated
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.
NCT00939783
·
Mobile, Alabama and 104 others
Completed
Cholinesterase Inhibitor Discontinuation
This study tries to determine if stopping certain medications that are used to treat dementia will cause worsening from the patient and family perspective.
NCT02248636
·
Little Rock, Arkansas and 3 others
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
NCT04777409
·
Phoenix, Arizona and 497 others
Terminated
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical…
NCT02565511
·
Phoenix, Arizona and 128 others
Terminated
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are 2:107,510,000-107,540,000…
NCT05267535
·
Costa Mesa, California and 36 others
Terminated
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease.
NCT02080364
·
Phoenix, Arizona and 114 others
Recruiting
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
The study will be conducted in 2 blinded parts (Part 1 and Part 2).
NCT06996730
·
Medellín, Antioquia
Completed
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB…
NCT00209456
·
Ismaning
Terminated
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.
NCT00954590
·
Santiago and 1 other
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
NCT04777396
·
Phoenix, Arizona and 446 others
Completed
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks.
NCT04994483
·
Chandler, Arizona and 87 others
Completed
Oculomotor Testing in the Differential Diagnosis of Dementia
The aim of this study is to determine whether saccadic eye movement recording may help in the discrimination between Lewy body dementia and Alzheimer disease, in the early stages…
NCT01577394
·
Paris
Recruiting
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
The goal of this clinical study is to learn if the study drug DMB-I (INN: Latrepirdine) works to treat Alzheimer type dementia in adults.
NCT07251023
·
Kazan' and 11 others
Completed
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts.
NCT00838110
·
Mobile, Alabama and 117 others
Completed
Effect of Indomethacin on the Progression of Alzheimer's Disease
The purpose of this study is determine whether indomethacin is able to retard disease progression in patients with mild to moderate Alzheimer's disease.
NCT00432081
·
Arnhem and 1 other
Completed
ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)
The study is designed to investigate the activity of the hormone drug leuprolide acetate in stabilizing cognitive function in mild-to-moderate AD patients.
NCT00231946
·
Peoria, Arizona and 58 others
Completed
Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study
CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD).
NCT00053599
·
Birmingham, Alabama and 43 others
Back
1
2
3
···
17
1 / 17
Next
Data from
ClinicalTrials.gov
Terms
